logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Astex Therapeutics Limited


USPTO Granted Patents = 126

% Expired Patents = 38.1



Trademarks = 6

Forward Citations = 1,122

Loading Chart...
Loading Chart...

220 inventors (with patents filed for the assignee):

goldMedal Valerio Berdini (40 out of 44 patents)

silverMedal Gordon Saxty (38 out of 42 patents)

bronzeMedal Christopher William Murray (34 out of 53 patents)

4.  Gianni Chessari (31 out of 32 patents)

5.  Steven Howard (28 out of 37 patents)

6.  Alison Jo-Anne Woolford (26 out of 29 patents)

7.  Maria Grazia Carr (22 out of 22 patents)

8.  Charlotte Mary Griffiths-Jones (20 out of 24 patents)

9.  Christopher Norbert Johnson (20 out of 62 patents)

10.  Paul Graham Wyatt (19 out of 24 patents)

11.  Miles Stuart Congreve (18 out of 96 patents)

12.  Andrew James Woodhead (18 out of 22 patents)

13.  Ildiko Maria Buck (17 out of 32 patents)

14.  Gilbert Besong (17 out of 22 patents)

15.  Martyn Frederickson (16 out of 16 patents)


Core Competencies:
Isoindolinone Inhibitors
FGFR Modulators
NRF2 Activators
Bicyclic Heterocycles
Pyrazole Compounds
Pharmaceutical Compositions
Combination Therapy
Protein Kinase Inhibitors
Naphthyridine Derivatives
Quinoxaline Derivatives
Hydroxybenzamide Derivatives
Pyrrolopyrimidine Compounds

126 patents:

1. 12741956 - Pyrazolyl quinoxaline kinase inhibitors (2026-09-22),
2. 12702658 - Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C (2026-08-11),
3. 12673041 - 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALT THEREOF (2026-07-07),
4. 12202828 - Bicyclic heterocycle compounds and their uses in therapy (2025-01-21),
5. 12091409 - Ether linked triazoles as NRF2 activators (2024-09-17),
6. 12077526 - Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them (2024-09-03),
7. 12071429 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2024-08-27),
8. 11918576 - Combination of an FGFR inhibitor and a CMET inhibitor (2024-03-05),
9. 11866428 - Bicyclic heterocycle compounds and their uses in therapy (2024-01-09),
10. 11684620 - Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine (2023-06-27),
11. 11643410 - Bicyclic heterocycle compounds and their uses in therapy (2023-05-09),
12. 11603367 - Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them (2023-03-14),
13. 11261171 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2022-03-01),
14. 11236047 - Combination of isoindolinone derivatives with SGI-110 (2022-02-01),
15. 11225476 - Bicyclic heterocycle compounds and their uses in therapy (2022-01-18),
Astex Therapeutics Limited, based in Cambridge, UK, specializes in the development of innovative cancer therapeutics. The company focuses on a range of core technologies, including isoindolinone inhibitors, FGFR modulators, and NRF2 activators, aimed at addressing various oncological challenges. Astex is recognized for its expertise in bicyclic heterocycles and pyrazole compounds, contributing to the advancement of pharmaceutical compositions and combination therapies, particularly in the realm of protein kinase inhibitors.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Astex Therapeutics Limited
126 Patents

#7 in Cambridge

#132 in United Kingdom

#6,358 in the World

Cambridge, GB
Cambridge, United Kingdom

Astex Therapeutics Limited

Forward Citations = 1,122

220 inventors:

goldMedal Valerio Berdini (40 out of 44 patents)

silverMedal Gordon Saxty (38 out of 42 patents)

bronzeMedal Christopher William Murray (34 out of 53 patents)

4.  Gianni Chessari (31 out of 32 patents)

5.  Steven Howard (28 out of 37 patents)

Please report any incorrect information to [email protected]
Loading…